Loading...
•
Sep 30, 2020
Veracyte Q3 2020 Earnings Report
Veracyte's Q3 2020 financial results showed a rebound to pre-pandemic levels, driven by the Afirma franchise, and key reimbursement and clinical-evidence milestones were achieved.
Key Takeaways
Veracyte announced a strong rebound in business during the third quarter, with revenue returning to pre-pandemic levels at $31.1 million. The company achieved important reimbursement and clinical-evidence milestones and remains on track to launch four new clinical products in 2021.
Revenue for the third quarter of 2020 was $31.1 million.
Product and testing revenue increased by 79% over the second quarter of 2020.
Gross Margin was 67% for the third quarter of 2020.
Net Loss and Comprehensive Loss was $4.1 million for the third quarter of 2020.
Revenue by Segment
Forward Guidance
Due to the continued uncertainties with respect to the COVID-19 pandemic, the company will not be providing guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...